Medical Advisory Board

Parabiotic's Medical Advisory Board is comprised of six key opinion leaders in the fields of gastroenterology, infectious disease, pulmonology, and integrated medicine.
Dr. Ellen Scherl, Professor of Clinical Medicine, Roberts Center for Inflammatory Bowel Disease, New York Presbyterian/Weill-Cornell Medical Center, who will be the Principal Investigator.  Weill-Cornell Medical Center will be the lead group in the Phase II study.

Dr. James George, Clinical Instructor Gastroenterology—Crohn’s, Colitis, IBS, Mt. Sinai Hospital-Icahn School of Medicine, New York.

Dr. William Suozzi, Associate Professor, Internal Medicine, Mount Sinai Hospital, New York

Dr. Louis Depalo, Sarah and Eric Lane Professor of Pulmonary Medicine, Mount Sinai Hospital, New York

Dr. Bhaswati Bhattacharya, Director, Dinacharya Institute Ayurvedic Medicine New York- India

Dr. Leo Galland, Professor, Foundation for Integrated Medicine, Nutritional Medicine & Gastrointestinal Pathology, New York



PARABIOTIC is led by a seasoned team experienced in business management as well as commercializing technologies through patent and FDA processes in developing companies.

Ira Trachtman, Founder/Chairman, has been a successful business executive with 40 years’ experience that includes new product development and medical research. Mr. Trachtman has started several companies and managed them to successful entities. As a former sufferer of ulcerative colitis for 35 years and now in remission for seven years, his personal observations of various treatment options and in-depth discussions with key opinion leaders in the fields of gastroenterology and infectious disease has resulted in Parabiotic’s patented Method for Treatment for patients. In addition, Trachtman has documented and analyzed over 30,000 pages of data and articles from leading researchers worldwide that has formed the basis behind Parabiotic’s rationale for treatment that implicates a pathogenic bacterial pathway as a causal factor in the pathogenesis of this insidious disease.

Aris Despo, CEO, is a seasoned executive with 30 years of leadership and business experience in monetizing technologies and intellectual property assets. His experience has included FDA project clearances and clinical studies with key opinion leaders at the Mayo Clinic, Johns Hopkins, VCU Massey Cancer Center and University of Wisconsin. Aris was Founder and CEO of a successful specialty chemical manufacturing company he started in 1981, Despo Chemicals International, and operated the company until being acquired by Ecolab in the late 1990’s. Aris holds a BA in chemistry from Washington & Jefferson College, MSc in organic chemistry from University of South Carolina and a MBA in Finance from Rutgers University.

Donald B. Carlin, PhD, President, has over 30 years’ experience in medical field product development, intellectual property, and contract management.  He has held senior executive positions at Sarnoff Corporation, LuxPhotonics, and Cardiovascular Solutions.  He earned degrees from MIT and his PhD from Yale. He did post-doctoral research at Harvard.

Eric Hagestad, PhD, Consultant/Advisor to the Board of Directors has broad experience in pharmaceutical product development.  Dr. Hagestad held senior levels positions at Bristol-Myers Squibb for over 22 years.  Dr. Hagestad received his bachelor’s degree from UCLA and his PhD from Harvard Medical School.